Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International, plc is asking shareholders to vote on eight proposals at its 2026 Annual Meeting on May 29, 2026 at its London offices. Holders of Class A ordinary shares have one vote per share and Class B ordinary shares have ten votes per share as of the April 6, 2026 record date.
Proposals include re-electing three Class II directors until the 2029 meeting, appointing and ratifying PricewaterhouseCoopers LLP as UK statutory auditors and US independent registered public accounting firm, authorizing the Audit Committee to set PwC’s UK audit fees, and receiving the UK statutory annual report for 2025.
Shareholders are also being asked to approve, on an advisory basis, the UK Statutory Directors’ Remuneration Report, approve an updated UK Remuneration Policy governing director pay for up to three years, and cast a non-binding Say-on-Pay vote on compensation for named executive officers.
Kiniksa Pharmaceuticals International, plc chief accounting officer Michael R. Megna reported an open-market sale of 6,625 Class A Ordinary Shares at $46.69 per share on April 9, 2026. After this transaction, he directly holds 27,418 shares. The filing notes the sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than timed discretionarily.
Kiniksa Pharmaceuticals International, plc chief operating officer Moat Ross reported an open-market sale of 1,703 Class A Ordinary Shares on April 9, 2026 at $46.69 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan entered on November 13, 2024, and Ross now directly holds 12,029 shares.
Kiniksa Pharmaceuticals, Ltd. Form 144 notice lists proposed sales of Class A ordinary shares tied to equity compensation and a restricted stock lapse. The excerpt shows a 04/07/2026 restricted-stock lapse and a proposed sale quantity listed as 79,513.00, plus a recent reported sale of 114,989.00 shares on 04/06/2026.
Kiniksa Pharmaceuticals International, plc filed a Form 144 reporting proposed dispositions of Class A ordinary shares. The filing lists a total of 6,625 shares tied to restricted stock lapses on 04/01/2026 (4,359 shares) and 04/07/2026 (2,266 shares).
Kiniksa Pharmaceuticals International, plc chief strategy officer Eben Tessari exercised Restricted Share Units into common shares and had shares withheld for taxes. On April 7, 2026, 2,726 RSUs were converted into 2,726 Class A Ordinary Shares. Of these, 846 shares at $48.94 per share were withheld to satisfy tax obligations, leaving Tessari with 23,130 Class A Ordinary Shares held directly. Each RSU represents a right to receive one Class A Ordinary Share and the RSU grant vests in four equal annual installments starting on April 7, 2023, over a four-year period.
Kiniksa Pharmaceuticals International, plc chief financial officer Mark Ragosa exercised 2,694 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Each RSU converts into one share and is part of a grant that vests in four equal annual installments starting April 7, 2022.
To cover tax obligations from this vesting, 1,303 Class A Ordinary Shares were withheld at a price of $48.94 per share, rather than sold in the open market. After these compensation-related transactions, Ragosa directly holds 16,154 Class A Ordinary Shares.
Kiniksa Pharmaceuticals International, plc Chairman & CEO Sanj K. Patel reported multiple equity transactions in the company’s Class A Ordinary Shares. On April 6, 2026, he exercised options for 7,278 shares at $10.36 per share and sold 7,278 shares at a weighted average price of about $50.01 in an open-market transaction executed under a pre-arranged Rule 10b5-1 trading plan.
On April 7, 2026, 9,991 Restricted Share Units converted into the same number of Class A Ordinary Shares, credited to The Patel Family Irrevocable Trust of 2025. Of these, 4,831 shares were withheld at $48.94 per share to cover tax obligations, leaving 76,174 shares in that trust. Additional indirect holdings include 109,795 shares in The Marina 2016 Irrevocable Trust and 51,794 shares in The Anglia 2013 Revocable Trust.
Kiniksa Pharmaceuticals’ chief medical officer John F. Paolini exercised 2,497 Restricted Share Units into Class A Ordinary Shares on April 7, 2026. Of these shares, 1,208 were withheld at $48.94 per share to cover tax obligations, and he now directly holds 65,623 Class A Ordinary Shares. The RSUs come from a grant that vests over four years, with 25% vesting on each anniversary of the April 7, 2022 grant date.